Document is current
Any future updates will be listed below
-
Authors
Galluzzi, Lorenzo
Bolini, Lukas
Shulman, Rebecca M.
- License Information
-
More Information
Article History
Received: 30 June 2025
Accepted: 18 July 2025
First Online: 1 August 2025
Competing interests
: L.G. is/has been holding research contracts with Lytix Biopharma, Promontory, and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, AbbVie, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. LB and RMS have no conflicts to declare.
